Clover Health Investments (CLOV) AI Stock Analysis

• Market Cap: $1.31B
• Dividend Yield: N/A
• Average Volume (3M): 3.93M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: 15.23%
• EPS Growth: 38.79%
• Country: US
• Employees: 570
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Plans
• EPS (TTM): -0.05
• Shares Outstanding: 424,304,900
• 10 Day Avg. Volume: 4,453,238
• 30 Day Avg. Volume: 3,927,246
• PEG Ratio: 0.45
• Price to Book (P/B): 4.52
• Price to Sales (P/S): 1.13
• P/FCF Ratio: 46.37
• Enterprise Value/Market Cap: 1.20
• Enterprise Value/Revenue: 0.88
• Enterprise Value/Gross Profit: 4.18
• Enterprise Value/Ebitda: -27.97
• 1Y Price Target: $3.35
• Price Target Upside: 32.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $2.50 ▼(-1.19% Downside)

The score is held down primarily by inconsistent cash generation and continued GAAP losses despite improving margins and a strong (zero-debt) balance sheet. Technicals also remain bearish with the price below key moving averages. The earnings call adds some support via strong growth and a path toward 2026 profitability, but lowered 2025 profitability guidance and elevated medical costs limit the upside, and valuation lacks support due to negative earnings and no dividend.

Positive Factors

Medicare Advantage Membership Growth

Strong membership growth in Medicare Advantage indicates successful market penetration and customer retention, supporting long-term revenue stability.

Improved Star Ratings

High star ratings enhance Clover's competitive position, potentially increasing CMS bonuses and attracting more members, boosting future revenue.

Strong Financial Position

A strong cash position provides financial flexibility for strategic investments and operational stability, supporting long-term growth initiatives.

Negative Factors

Declining Revenue Trends

Declining revenue poses a risk to financial health, indicating challenges in maintaining market share and necessitating strategic adjustments for recovery.

Negative Margins

Persistent negative margins highlight ongoing profitability challenges, which could hinder reinvestment capabilities and long-term financial sustainability.

Higher SG&A Expenses

Rising SG&A expenses can pressure profitability, requiring efficient cost management to ensure investments translate into sustainable growth.

Clover Health Investments Business Overview & Revenue Model

Company Description

Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.

How the Company Makes Money

Clover Health makes money primarily through its Medicare Advantage plans, where it receives a fixed monthly payment from the Centers for Medicare & Medicaid Services (CMS) for each enrolled member. This payment is used to cover healthcare costs for members, allowing Clover to profit from efficiently managing these costs through improved care and preventative measures. The company's revenue model is heavily reliant on its ability to reduce medical expenses through data-driven insights provided by the Clover Assistant, which aims to optimize treatment plans and improve patient outcomes. Significant partnerships with healthcare providers and a focus on expanding its member base within the Medicare Advantage market are key factors contributing to its earnings.

Clover Health Investments Financial Statement Overview

Summary

Clover Health Investments shows signs of improvement in cash flow and equity position, but continues to face challenges in revenue growth and profitability. The income statement highlights ongoing struggles with negative margins, while the balance sheet demonstrates a stronger equity position with zero debt. Despite these improvements, the company must address its revenue decline and work towards achieving profitability for long-term financial health.

Income Statement

Clover Health Investments has faced declining revenue trends, with a notable drop from $3.47 billion in 2022 to $1.37 billion in 2024. The company has consistently reported negative net income and EBIT margins, indicating ongoing profitability challenges. The net profit margin remains negative, further emphasizing financial struggles, despite a slight improvement in gross profit margin from 2023 to 2024.

Balance Sheet

The balance sheet shows some positive aspects with a debt-free position by 2024 and improving stockholders' equity. However, the equity ratio is moderate at approximately 58.7%, and the historical negative equity in 2020 indicates past financial instability. The return on equity remains negative due to persistent net losses.

Cash Flow

The cash flow statement reveals a significant turnaround in operating cash flow from negative $115.87 million in 2023 to positive $82.45 million in 2024, resulting in positive free cash flow. However, the company's history of negative free cash flow raises concerns about sustainable cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.77B	1.37B	1.26B	1.10B	1.47B	672.89M
Gross Profit	375.61M	364.80M	255.95M	103.48M	-79.18M	82.81M
EBITDA	-56.10M	-44.94M	-207.63M	-252.03M	-569.60M	-78.73M
Net Income	-58.32M	-43.01M	-213.36M	-339.57M	-587.76M	-136.39M
Balance Sheet
Total Assets	559.66M	580.74M	570.67M	808.62M	950.80M	267.25M
Cash, Cash Equivalents and Short-Term Investments	202.84M	221.54M	242.69M	334.76M	615.25M	96.71M
Total Debt	0.00	0.00	4.66M	5.86M	27.83M	138.36M
Total Liabilities	218.73M	239.60M	284.28M	451.73M	411.49M	880.45M
Stockholders Equity	340.93M	341.14M	286.39M	356.89M	535.41M	-617.10M
Cash Flow
Free Cash Flow	-86.38M	33.29M	-116.45M	-208.39M	-283.05M	-119.19M
Operating Cash Flow	-84.61M	34.84M	-115.87M	-203.93M	-282.33M	-118.50M
Investing Cash Flow	37.63M	565.00K	140.01M	95.13M	-435.45M	141.31M
Financing Cash Flow	-50.92M	-17.36M	-33.86M	-4.96M	925.39M	1.94M

Clover Health Investments Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLOV, the sentiment is Negative. The current price of 2.53 is below the 20-day moving average (MA) of 2.56, below the 50-day MA of 2.66, and below the 200-day MA of 2.96, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 48.49 is Neutral, neither overbought nor oversold. The STOCH value of 54.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLOV.

Clover Health Investments Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MOH	71 Outperform	$9.43B	11.37	19.71%	―	13.71%	-18.02%
HUM	69 Neutral	$33.38B	25.95	7.15%	1.38%	9.87%	-5.58%
ALHC	60 Neutral	$4.19B	-179.83	-15.06%	―	47.39%	85.35%
CNC	58 Neutral	$23.06B	-4.34	-21.93%	―	14.92%	-286.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLOV	46 Neutral	$1.31B	-21.85	-16.90%	―	15.23%	38.79%
OSCR	45 Neutral	$4.47B	-15.03	-22.32%	―	37.38%	-912.18%

Clover Health Investments Corporate Events

Clover Health Unveils Counterpart Assistant Adoption

On December 10, 2025, Clover Health Investments announced the performance outcomes of its subsidiary, Counterpart Health, Inc., and the adoption of its Counterpart Assistant technology by third-party customer clinicians. This development highlights the company’s strategic efforts to expand its technology solutions in the healthcare sector, particularly for Medicare-eligible populations, potentially impacting its market position and stakeholder interests.

The most recent analyst rating on (CLOV) stock is a Buy with a $3.70 price target. To see the full list of analyst forecasts on Clover Health Investments stock, see the CLOV Stock Forecast page.

Clover Health Addresses Shareholder Concerns Post Q3 Earnings

On November 12, 2025, Clover Health Investments released a supplemental Q&A to address shareholder questions following their third quarter 2025 earnings announcement. The company reported elevated medical cost pressures due to increased utilization among new member cohorts, which impacted margins. Despite these challenges, Clover Health remains optimistic about 2026, citing a 4 Star payment year, favorable rate updates, and increased Clover Assistant coverage as factors that will enhance profitability and growth. The company is also implementing initiatives to improve pharmacy management and customer service to strengthen its Star Ratings, which have been affected by non-clinical factors.

The most recent analyst rating on (CLOV) stock is a Buy with a $3.70 price target. To see the full list of analyst forecasts on Clover Health Investments stock, see the CLOV Stock Forecast page.

Chelsea Clinton Departs Clover Health Board of Directors

On October 31, 2025, Chelsea Clinton announced her departure from Clover Health’s Board of Directors after over eight years of service. Her tenure saw Clover’s transformation from a private company to a publicly traded entity serving over 100,000 seniors. Clinton’s contributions were pivotal in shaping the company’s mission-driven approach and technological advancements in healthcare. The Board plans to fill her vacancy promptly, maintaining its commitment to a diverse and experienced leadership team.

The most recent analyst rating on (CLOV) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Clover Health Investments stock, see the CLOV Stock Forecast page.

Clover Health Announces 2026 Medicare Star Ratings

On October 9, 2025, Clover Health Investments announced the Centers for Medicare & Medicaid Services’ 2026 Star Ratings for its Medicare Advantage plans, with its PPO plans receiving 3.5 Stars and its HMO plan receiving 4.0 Stars. Despite these ratings, Clover Health is confident in its ability to drive above-market membership growth and increasing profitability through its technology-centric care strategy and AI-driven improvements in its Clover Assistant platform. The company emphasizes that its business model can sustain growth and profitability independent of the Star ratings, as demonstrated by its strong revenue and membership growth in the first half of 2025. Clover Health also highlights its high clinical quality scores and ongoing engagement with CMS to ensure its ratings reflect its health outcomes.

The most recent analyst rating on (CLOV) stock is a Buy with a $4.10 price target. To see the full list of analyst forecasts on Clover Health Investments stock, see the CLOV Stock Forecast page.